前收市價 | 3.0300 |
開市 | 3.0300 |
買盤 | 0.0000 |
賣出價 | 4.6000 |
拍板 | 23.00 |
到期日 | 2025-06-20 |
今日波幅 | 3.0300 - 3.0300 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 1 |
While innovations such as artificial intelligence have become all the rage, there’s another type of technology – biotechnology – that deserves careful consideration for your portfolio. Indeed, if you haven’t considered the sector, it’s really time to focus on biotech stocks. First, let’s get the obvious matter out of the way: biotech stocks benefit broadly from a permanently relevant narrative. That doesn’t mean individual companies are guaranteed to rise. It’s just that the concept of addressin
Corcept's (CORT) pipeline progress has been encouraging with relacorilant currently under evaluation for Cushing's syndrome. The NDA for relacorilant is expected to be filed in the third quarter.
I’m on the hunt for ‘Strong Buy’ biotech stocks. According to Finviz.com, there are 680 U.S.-listed biotech stocks. Of those, 73 have a market capitalization of $2 billion or greater, with 44 rated ‘Strong Buy.’ Which ones to buy? I’m admittedly not a biotech junkie, so I’m interested in businesses that are close to profitability. That’s tough for this particular industry where drug development is obscenely expensive. InvestorPlace - Stock Market News, Stock Advice & Trading Tips However, of the